BioGaia has been granted a patent for lactic acid bacterial strains capable of producing melatonin and adenosine for therapeutic use in treating diseases associated with melatonin deficiency, such as infantile colic. The patented strains include Lactobacillus reuteri DSM 32846, DSM 32847, DSM 32849, or DSM 33198. GlobalData’s report on BioGaia gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioGaia, Lactobacillus probiotics was a key innovation area identified from patents. BioGaia's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Lactic acid bacterial strains producing melatonin for therapeutic uses
A recently granted patent (Publication Number: US11911424B2) discloses a bacterial strain, specifically Lactobacillus reuteri DSM 32846, DSM 32847, DSM 32849, or DSM 33198, with potential therapeutic applications. The patent claims cover the use of these bacterial strains in dried form for increasing the production of melatonin or adenosine in a subject. Additionally, a combination product is described, comprising the Lactobacillus reuteri strain along with a further source of melatonin and/or adenosine, or substrate components to enhance the production of these compounds by the bacterial strain.
Furthermore, the patent outlines methods for producing or inducing the production of melatonin or adenosine in a subject by administering the Lactobacillus reuteri strain. The composition containing at least one of these bacterial strains is proposed for treating conditions such as irritable bowel syndrome (IBS), sleep disorders, neurodegenerative diseases, and infantile colic. The methods involve administering a therapeutically effective amount of the Lactobacillus reuteri strain, potentially leading to a significant increase in the levels of melatonin and/or adenosine in the subject, up to 5 fold compared to pre-administration levels. Additionally, the patent suggests the use of further substrate components or agents, such as AMP (adenosine monophosphate), to enhance the production of these compounds in the subject, either in combination with the bacterial strain or separately.
To know more about GlobalData’s detailed insights on BioGaia, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
